Home » Clinical Trials » Beta thalassemia » NCT06479616
NCT06479616

A Long-term Follow-up Study Evaluating the Safety and Efficacy of Subjects With β-thalassemia Treated With Base-edited Autologous Hematopoietic Stem Cell (CS-101) Transplantation

Study Summary

This is a study to evaluate the long-term safety and efficacy of CS-101 in participants who received CS-101 in study CS -101-03 (NCT06065189)

Want to learn more about this trial?

Request More Info

Interventions

CS-101GENETIC
Autologous CD34+ hematopoietic stem cell suspension modified by in vitro base editing technique

Study Locations

FacilityCityStateCountry
Children's Hospital of Fudan UniversityShanghaiShanghai MunicipalityChina

Official Trial Information

View on ClinicalTrials.gov

Data sourced from ClinicalTrials.gov. Last updated: April 14, 2026